0000950170-24-022485.txt : 20240228 0000950170-24-022485.hdr.sgml : 20240228 20240228194157 ACCESSION NUMBER: 0000950170-24-022485 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VAN NOSTRAND ROBERT L CENTRAL INDEX KEY: 0001225198 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 24698167 MAIL ADDRESS: STREET 1: C/O ACHILLION PHARMACEUTICALS, INC. STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 ownership.xml 4 X0508 4 2024-02-27 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001225198 VAN NOSTRAND ROBERT L C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 true false false false false Common Stock 2024-02-27 4 M false 20000 18.56 A 29611 D Common Stock 2024-02-27 4 S false 9651 72.71 D 19960 D Common Stock 2024-02-27 4 S false 10349 73.14 D 9611 D Stock Option (right to buy) 18.56 2024-02-27 4 M false 20000 0.00 D 2024-03-21 Common Stock 20000 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0016 to $73.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.0026 to $73.42, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. This option was granted on March 21, 2014 and will expire on March 21, 2024. All shares underlying this option have vested. /s/ Lawrence J. Hineline, Attorney-in-fact 2024-02-28